Cambridge Investment Research Advisors
NRXP icon

Cambridge Investment Research Advisors’s NRX Pharmaceuticals NRXP Stock Holding History

Cambridge Investment Research Advisors’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-15,352
Closed -$1.42M – 3244
2021
Q3 		$1.42M Buy
+15,352
New +$2M 0.01% 1286

Other funds holding NRXP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Cambridge Investment Research Advisors's NRXP Position: Q4 2021 in Review

Cambridge Investment Research Advisors sold out of NRX Pharmaceuticals (NRXP) in Q4 2021, closing a stake of 15,352 shares — an estimated $1.42M sold.

Cambridge Investment Research Advisors first reported a position in NRXP in Q3 2021 and held it in 1 quarter. The position peaked at $1.42M in Q3 2021. 38 funds tracked by Wall St. Rank hold NRXP as of Q4 2021.

  • Cambridge Investment Research Advisors reported no remaining NRX Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 15,352 NRX Pharmaceuticals shares in Q4 2021, an estimated $1.42M.
  • Cambridge Investment Research Advisors first reported a position in NRX Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • Cambridge Investment Research Advisors's NRX Pharmaceuticals position peaked at $1.42M in Q3 2021.
  • 38 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q4 2021.

Based on Cambridge Investment Research Advisors's 13F filing for Q4 2021, filed 3 Feb 2022.